PROFILE in Medical Technology

TWO NEW KLRI PEER-REVIEWED PUBLICATIONS: Hormone Therapy May Reduce Atherosclerosis in Women Close to Menopause; Growth Hormone May Increase Risk of Diabetes, Improve Lipid Profile in Men

PHOENIX, Aug. 3 /PRNewswire-USNewswire/ -- The Phoenix-based Kronos Longevity Research Institute (KLRI) has published two new publications on hormone therapies and their effects on reducing the risks of cardiovascular disease in older adults. Cardiovascular disease caused by ...

New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI)

PHILADELPHIA, May 22 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY ), the global specialty biopharmaceutical company, announced results of a study showing that coadministration of the ADHD medication VYVANSE(R) (lisdexamfetamine dimesylate) CII with the proton pump inhibitor (PP...

Agendia Supports High Profile CME Symposium and Presents Compelling Data at the 2008 San Antonio Breast Cancer Symposium

HUNTINGTON BEACH, California and AMSTERDAM, December 8 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, today announced that leading Agendia and the Netherlands Cancer Institute researchers will present data from multiple studies at the 2008 San Antonio Breast Cancer Sympos...

Established Safety Profile of Spiriva Confirmed by 30 Rigorously Controlled Clinical Trials and the Landmark Trial UPLIFT

New Data from Landmark UPLIFT Trial Further Supports Spiriva's Safety Profile RIDGEFIELD, Conn. and NEW YORK, Sept. 23 /PRNewswire/ -- Boehringer Ingelheim and Pfizer Inc have released a new analysis of 30 rigorously controlled clinical trials, including UPLIFT, confirming the long term safe...

Catheter Ablation System for Atrial Fibrillation Shows Reduced Procedure Time, Remarkable Safety Profile and Excellent Outcomes in Two Clinical Studies

Important Studies Presented at the European Society of Cardiology Continue to Bring Attention to Innovative Technology CARLSBAD, Calif., Sept. 2 /PRNewswire/ -- Ablation Frontiers, Inc., announced today that two important studies, involving its innovative atrial fibrillation ablati...

Studies of an Innovative Catheter Ablation System for Atrial Fibrillation Reveal Excellent Outcomes, Safety Profile and Fast Procedure Times

Presentations at Cardiostim World Congress Focus Attention on a New Ablation Technology CARLSBAD, Calif., June 24 /PRNewswire/ -- Ablation Frontiers, Inc. today announced that two studies reporting positive findings about its novel atrial fibrillation catheter ablati...

Positive Phase I/II Data of IDX899 Confirm Potent Antiviral Activity and Favorable Safety Profile in Treatment-Naive HIV-Infected Patients

CAMBRIDGE, Mass., June 12 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX ), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases, today reported phase I/II data for IDX899, a non-nucl...

New Meta-Analysis Confirms Safety Profile for NeoRecormon in Treating Anaemia in Cancer Patients

BASEL, Switzerland, June 11 /PRNewswire-FirstCall/ -- - Data Published in the British Journal of Cancer Reports That NeoRecormon use has no Negative Impact on Overall Survival or Tumour Progression A new meta-analysis of all 12 prospective, randomised, controlled studies in 2,301 cancer pa...

Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis

-- Phase 1 RDEA119 data expected in second half of 2008 -- -- Presentation at the Seventh Annual JMP Securities Research Conference on May 21st canceled; webcast of corporate update scheduled during Ardea's Annual Stockholder Meeting on May 22nd at 9:30 a.m. PT -- SAN DIEGO, May...

Imaging Results From the ADAGIO-LIPIDS Reveal That Effects of Rimonabant on Cardiometabolic Risk Profile Include Loss of Visceral Fat and Mobilization of Liver Fat

QUEBEC CITY, Canada, April 29 /PRNewswire/ -- At a late breaking presentation made on April 29th during the Annual meeting of the European Atherosclerosis Society held in Istanbul, the investigators of ADAGIO-LIPIDS presented the key findings of a one year trial aiming at further studying the ...

SuperGen's DNA Methyltransferase Inhibitor, S-110, Improves In Vivo Efficacy Profile of Decitabine

Restored sensitivity to cisplatin observed in ovarian carcinoma xenografts DUBLIN, Calif., April 14 /PRNewswire-FirstCall/ -- SuperGen Inc. (Nasdaq: SUPG ), a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematologi...

ANX-201 Demonstrates a Unique Resistance Profile in Preclinical Tests

ADVENTRX Presents Results at Keystone Symposia HIV Pathogenesis Conference SAN DIEGO, March 31 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: ANX ) announced that it presented preclinical results for ANX-201, the Company's broad-spectrum antiviral product candidate at the Keys...

Nuvelo Announces Phase 2 SONOMA-3 Trial Did Not Meet Target Product Profile and Discontinues Alfimeprase Development

-Webcast to Be Held at 4:30 p.m. ET today- SAN CARLOS, Calif., March 17 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq: NUVO ) today announced that data from the Phase 2 program in catheter occlusion (CO), known as SONOMA-3 (Speedy Opening of Non-functional and Occluded cathete...

Kosan Presents Phase 1 Data Showing Antitumor Activity and Safety Profile of Epothilone KOS-1584 at AACR/NCI/EORTC Meeting

HAYWARD, Calif., Oct. 23 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN ) presented updated data today from a Phase 1 clinical trial showing that KOS-1584/R1645, an epothilone under co-development with Roche, demonstrated antitumor activity and tolerability in patients...

Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference

SAN CARLOS, Calif., Oct. 10 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR ) announced today that preclinical data for its proprietary product candidate NKTR-102 (PEG-irinotecan) will be presented at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Th...

ALS TDI Completes Gene Expression Profile of Lou Gehrig's Disease in Mice

Largest Target-Discovery Program Aimed at New Treatments for Fatal Disease CAMBRIDGE, Mass., Oct. 2 /PRNewswire/ -- The ALS Therapy Development Institute (ALS TDI) today announced that it has completed the first phase of a comprehensive gene-expression database for ALS with the profiling of the...

Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent

While no significant differences were found, results showed CYPHER(R) Stent had lower mortality and heart attack rates VIENNA, Austria, Sept. 4 /PRNewswire/ -- A subgroup analysis of diabetic patient data from a two-year randomized controlled trial comparing the CYPHER(R) Sirolimus...

Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates

SAN DIEGO, Aug. 20 /PRNewswire-FirstCall/ -- Lpath, Inc. (OTC Bulletin Board: LPTN), the category leader in therapeutic agents against bioactive lipids, reported that a standard panel of safety tests was recently completed with the humanized version of Sphingomab(TM), and the findings indicate...

Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile

TAMPA, Fla., May 9 /PRNewswire-USNewswire/ -- Osteoarthritis is a painful and potentially debilitating condition that affects almost 50 million people in the United States. It is caused by deterioration of cartilage in bone joints. The novel investigational pain medication tapentadol, a central...

HUYA Bioscience Int'l Announces Clinical Trial Milestones in China for Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile

Progress validates HUYA's innovative U.S./China pharmaceutical co-development model SAN FRANCISCO, March 3 /PRNewswire/ -- IBC Conference -- HUYA Bioscience International (HUYA), the leader in U.S./China pharmaceutical co-development, today announced the completio...

Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile

-- Study concludes there was no evidence of the development of viral resistance to R7128 after 2 weeks of monotherapy in hepatitis C patients -- PRINCETON, N.J., Feb. 6 /PRNewswire-FirstCall/ -- Pharmasset (Nasdaq: VRUS) and Roche will present the R7128 monotherapy resistance profile at the ...

New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile

More than 10 data presentations demonstrate the safety and activity of MYCAMINE as an antifungal agent CHICAGO, Sept. 18 /PRNewswire/ -- New data from a pooled analysis of 17 clinical studies demonstrate that MYCAMINE(R) (micafungin sodium) for injection offers a favorable ...

Scientific Results Presented At ECCMID Demonstrate Well- Differentiated Profile of Basilea's Two Phase III Anti- infective Compounds

BASEL, Switzerland, April 3, 2007 (PRIME NEWSWIRE) -- New data presented at ECCMID highlight the microbiological and pharmacokinetic profiles of Basilea's (SWX:BSLN) two late-stage drug candidates ceftobiprole and isavuconazole. Studies reported both for ceftobiprole, the first anti-MRSA broad-spe...

Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR

Tanespimycin Shown to Have No Effect on QTc Interval HAYWARD, Calif., April 16, 2007 /PRNewswire/ -- Kosan Biosciences Incorporated today presented safety data from preclinical and clinical studies of its lead Hsp90 inhibitor, tanespimycin (KOS-953). Serial electrocardiogram (ECG) monitoring of pa...

Independent publication supports the profile of CeNeS phase II compound, CNS 5161

CAMBRIDGE, England, 4th May 2007 - CeNeS Pharmaceuticals plc (LSE: CEN), the Cambridge based biopharmaceutical company, notes the publication of an independent study in the respected scientific journal 'Synapse'* on its Phase II NMDA antagonist, CNS 5161. CeNeS is developing CNS 5161 as a potentia...

Efficacy and Safety Profile of Basilea's Alitretinoin for Severe Refractory Chronic Hand Eczema Confirmed by Data Shown at European Dermatology Congress

BASEL, Switzerland, May 21, 2007 - Results from phase III clinical trials and further human pharmacology studies were presented at the 16th Congress of the European Academy of Dermatology and Venereology (EADV). These data highlighted the efficacy and safety profile of alitretinoin as a potential ...

Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO

HAYWARD, Calif., June 04, 2007 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated presented data from a Phase 1 clinical trial showing that KOS-1584/R1645, an epothilone under co-development with Roche, demonstrated promising antitumor activity and tolerability in patients with solid tumors....

Phase IIIb Clinical Data Validate the Overall and Cardiovascular Safety Profile of Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) in Patients with Type 2 Diabetes

Data Also Support Drug's Efficacy at Improving Glycemic Control and Reducing Diabetic Cardiovascular Complications CHICAGO, Ill., June 23, 2007 /PRNewswire/ -- VeroScience, LLC, in conjunction with its commercialization partner S2 Therapeutics, Inc., reported today the results of its Phase IIIb cl...

Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop

PRINCETON, N.J.--(BUSINESS WIRE)--Jun 28, 2007 - Cytogen Corporation (NASDAQ: CYTO) reported updated data from a Phase 1 dose escalation study evaluating QUADRAMET(R) (samarium Sm-153 lexidronam injection) in combination with bortezomib (Velcade(R), Millennium Pharmaceuticals, Inc.) in patients wit...

Intercell AG: Novel tuberculosis Vaccine Shows Promising Immunogenicity and Safety Profile

» The Danish Statens Serum Institut (SSI) and Intercell report promising data from a phase I clinical trial with a tuberculosis (TB) subunit vaccine » The vaccine is produced by SSI and contains Intercell’s adjuvant IC31™ » ...

Two-Year Results from the Medtronic ENDEAVOR III Trial Confirm Stent's Positive Clinical Profile

MINNEAPOLIS--(BUSINESS WIRE)--Mar 26, 2007 - Two-year results from the Medtronic (MDT:NYSE) ENDEAVOR III trial confirm the positive clinical profile of the Endeavor(R) drug-eluting coronary stent and bring to nearly 1,300 the number of Endeavor patients who have at least two years of follow-up. Sig...

Antipsychotic Iloperidone Results Show Favorable Akathisia Profile

SAN DIEGO, May 22, 2007 /PRNewswire-FirstCall/ -- According to study results presented today at the 2007 American Psychiatric Association annual meeting, iloperidone, an investigational atypical antipsychotic, was shown to have a favorable akathisia profile. Akathisia -- a debilitating sensation o...

Vectibix(R) in Combination With Chemotherapy Significantly Improved Progression-Free Survival in First-Line Metastatic Colorectal Cancer

...first prospective Phase 3 data to demonstrate the utility of KRAS mutational analysis as a predictive biomarker." Overall, the adverse event profile was as anticipated for an anti-EGFR antibody in combination with oxaliplatin-based chemotherapy, including known events such as skin toxicity, hypomag...

2,500 Cases Completed With the Magnetic Irrigated Catheter

... With the diverse group of clinicians who now routinely use our Niobe system, we are particularly delighted that the system has maintained the safety profile for which it has become well known." About Stereotaxis Stereotaxis designs, manufactures and markets an advanced cardiology instrument con...

Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia

... SUSTENNA(TM) demonstrates our commitment to providing valuable novel therapies for schizophrenia. INVEGA(R) SUSTENNA(TM) has a demonstrated safety profile that can help healthcare professionals address the issue of medication adherence and can also help many patients delay the time to relapse." Vi...

Wyeth Reports Publication of Phase 3 Data for Bazedoxifene/Conjugated Estrogens, an Investigational Compound Being Studied for the Treatment of Menopausal Symptoms

...aluation of Bazedoxifene/Conjugated Estrogens (BZA/CE) for the Treatment of Menopausal Symptoms and Effects on Metabolic Parameters and Overall Safety profile (Lobo R, et al) Results from a sub-analysis suggest that treatment with BZA/CE significantly reduced the frequency and severity of hot flushe...

Unlikely Treatment Identified by BrainCells Neurogenesis Platform Improved Clinical Outcomes in Patients Suffering From Depression

...ents with MDD showed that BCI-952 demonstrated improvements in multiple endpoints of depression. In addition, BCI-952 was well tolerated with a safety profile similar to placebo. About BrainCells Inc. BrainCells Inc. (BCI) is a drug discovery and development company leading the scientific research...

NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study

... timing of the submission of clinical trial data; acceptance of clinical trial data by the FDA in support of regulatory approval; and the tolerability profile and/or benefits of its product candidates. Such statements are based on management's current expectations, but actual results may differ materially d...

Awardees for the 2009 Young Investigator Grant for Probiotics Research Announced

...ucts with health benefits based on scientific evidence. It also studies the effects of food on health and aims to continuously improve the nutritional profile of DANONE products worldwide. Probiotic research is a key expertise of DANONE RESEARCH. Over the past 90 years, DANONE has amassed a collect...

Poniard Pharmaceuticals Announces Positive Cardiac Safety Data From Picoplatin Phase 1 Trial Supporting NDA Filing

...signed to overcome platinum resistance associated with chemotherapy in solid tumors. Study data to date suggest that picoplatin has an improved safety profile relative to existing platinum-based cancer therapies. Results to date suggest that hematologic events are common but manageable. Kidney toxicity (neph...